title: Predictive biomarkers investigated in glioblastoma.
abstract: Glioblastoma is the most aggressive primary brain tumor in adults. Consequently, new therapeutic strategies are needed. Tumor response to cytotoxic chemotherapy is heterogeneous across patients. Interestingly, predictive biomarkers of response to these classic chemotherapeutic agents have been identified in neuro-oncology (i.e., 1p/19q co-deletion, IDH mutation and O6-methylguanine DNA-methyltransferase promoter methylation). The most emblematic biomarker in glioblastoma is O6-methylguanine DNA-methyltransferase promoter methylation that predicts response to temozolomide. In parallel, innovative drugs are emerging. Some of these agents have shown some activity but in a limited number of glioblastoma patients. One of the major challenges is to identify molecular predictors of response to these smart drugs for an efficient personalized medicine. These novel agents have been tested in clinical trials enrolling glioblastoma patients. Although none of them has been validated prospectively in Phase III clinical trials, interesting molecular predictors of response to these drugs have been investigated and are presented in this review, which also reports more advanced biomarkers.
authors.affiliation: AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, 47-83, Boulevard de l'Hôpital, 75013 Paris, France.
authors.forename: Emeline
authors.initials: E
authors.lastname: Tabouret
authors.forename: Olivier
authors.initials: O
authors.lastname: Chinot
authors.forename: Marc
authors.initials: M
authors.lastname: Sanson
authors.forename: Anderson
authors.initials: A
authors.lastname: Loundou
authors.forename: Khê
authors.initials: K
authors.lastname: Hoang-Xuan
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Delattre
authors.forename: Ahmed
authors.initials: A
authors.lastname: Idbaih
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D001932:Brain Neoplasms / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D019175:DNA Methylation / Q000235:genetics*; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005909:Glioblastoma / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D019853:O(6)-Methylguanine-DNA Methyltransferase / Q000235:genetics; D011401:Promoter Regions, Genetic / Q000235:genetics; D000077204:Temozolomide
chemical_list: D020533:Angiogenesis Inhibitors; D018906:Antineoplastic Agents, Alkylating; D014408:Biomarkers, Tumor; D003606:Dacarbazine; D019853:O(6)-Methylguanine-DNA Methyltransferase; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077204:Temozolomide
keywords: MGMT; biomarker; chemotherapy; glioblastoma; molecular; predictive; targeted therapy